Nippon India Pharma Fund
NAV
₹642.89
as of 21 Aug 2026
Nippon India Pharma Fund is an open-ended Sectoral/ Thematic scheme from Nippon India Mutual Fund managing ₹9,279 crore (as of 31 Jul 2026). Its Direct-plan NAV is ₹642.89 as of 21 Aug 2026. The expense ratio is 0.79% a year. Managed by Sailesh Raj Bhan. This page is factual data only — it carries no rating and no recommendation.
Key facts
- Expense ratio
- 0.79% / yr
- as of 30 Jun 2026
- Fund size
- ₹9,279 crore
- as of 31 Jul 2026
- Exit load
- 1%
- SIP available
- Yes
- Launched
- 5 Jun 2004
- ISIN
- INF204K01I50
₹100 invested, fund vs category
The category line is the average of the funds in this category, built from NYVO’s own NAV data.
Rebased to 100data to 20 Aug 2026Benchmark: Nifty Pharma TRI
Nippon India Pharma Fund
₹198
+98% on ₹100 over 5.0 yrs
Sectoral/ Thematic average
₹210
+110% on ₹100 over 5.0 yrs
Returns vs category
| Window | Fund | Category avg | Gap |
|---|---|---|---|
| 3 months | 5.81% | 6.78% | -0.97 |
| 6 months | 12.46% | 3.68% | +8.78 |
| 1 year | 10.93% | 6.07% | +4.86 |
| 3 years (CAGR) | 18.91% | 16.01% | +2.90 |
| 5 years (CAGR) | 14.51% | 15.20% | -0.69 |
Category average across 119 funds, as of 21 Aug 2026. Short windows are noise; the 3 and 5-year rows are the record. Past returns do not predict future returns.
A single return number depends on its start date. These are ALL the overlapping holding periods, so the worst case is visible — read that number first.
1-year holding periods
- Worst
- -11.8%
- Median
- 11.8%
- Best
- 61.5%
49 windows over the last 60 months, stepped monthly; 74% ended positive. Worst window began 1 Sept 2021. Windows overlap — this is the range of past start dates, not a probability of anything.
3-year holding periods (per year)
- Worst
- 17.2%
- Median
- 21.9%
- Best
- 26.4%
25 windows over the last 60 months, stepped monthly; 100% ended positive. Worst window began 2 Aug 2021. Windows overlap — this is the range of past start dates, not a probability of anything.
Risk, measured
- Sharpe ratio (3Y)
- 0.87
- Sharpe ratio (5Y)
- 0.57
- Sortino ratio (3Y)
- 1.45 vs category 1.55
- Standard deviation (3Y)
- 14.77%
- Beta (3Y)
- 0.88
- Alpha (3Y)
- -0.72%
- Deepest fall (5Y)
- -16.58%
Distance below its own peak
Every dip below 0 is the fund trading under a previous high — how deep and for how long is what a drawdown feels like.
Deepest fall
-14.2%
Right now
-0.8% below peak
Ahead of its benchmark in 33% of months (window: 3y, monthly) — benchmark: Nifty Pharma TRI, name shown only.
Where the money actually is
Equity
97.3%
Cash
2.7%
Whole-portfolio split, as of 31 Jul 2026.
What it owns
38 positions · top 10 = 57.3%
Market-cap mix
Large 31.1%Mid 38.6%Small 27.6%Other 2.7%
as of 31 Jul 2026
Holdings by sector
Healthcare(10 in top 10)97.3%
- Sun Pharmaceuticals Industries Ltd13.31%
- Lupin Ltd7.25%
- Divi's Laboratories Ltd6.52%
- Cipla Ltd6.03%
- Apollo Hospitals Enterprise Ltd5.30%
- Dr Reddy's Laboratories Ltd5.01%
- Mankind Pharma Ltd3.74%
- Sai Life Sciences Ltd3.62%
- Ajanta Pharma Ltd3.41%
- Max Healthcare Institute Ltd Ordinary Shares3.15%
Sectors marked ▶ expand to show this fund’s top-10 holdings in that sector. Holdings as of 31 Jul 2026. Portfolio turnover 14.3% vs category 37.3% a year.
The businesses it owns
- P/E (trailing)
- 39.6 vs category 25.8
- P/B
- 5.8 vs category 3.8
- Dividend yield
- 0.8% vs category 1.1%
- Net margin
- 16.0% vs category 15.4%
- Earnings growth
- 10.0%
- Avg market cap
- ₹71,587 crore
Money in, money out
- Net flow, 12 months
- −₹80 cr
- Net flow, 3 months
- +₹61 cr
as of 31 Jul 2026. Flows follow performance more than they predict it.
Quick answers
- What is the NAV of Nippon India Pharma Fund?
- ₹642.89 per unit as of 21 Aug 2026 (Direct plan, growth). NAV is declared daily on working days.
- What is the expense ratio of Nippon India Pharma Fund?
- 0.79% a year for the Direct plan, as of 30 Jun 2026.
- How large is Nippon India Pharma Fund?
- ₹9,279 crore under management as of 31 Jul 2026, in the Sectoral/ Thematic category.
- How risky is Nippon India Pharma Fund?
- Its SEBI Riskometer reading is "Very High Risk". One sector, one story. The most-launched shelf on the map, by far.
- What are the 5-year returns of Nippon India Pharma Fund?
- 14.51% a year over the last 5 years (Direct plan, CAGR), against a Sectoral/ Thematic average of 15.20%. Past returns do not predict future returns.
- What is the worst 3-year return of Nippon India Pharma Fund?
- 17.2% a year — the weakest of 25 overlapping 3-year holding periods, beginning 2 Aug 2021. The median was 21.9% and 100% of those windows ended positive. Windows overlap, so this is the range of past start dates, not a probability.
- Who manages Nippon India Pharma Fund?
- Sailesh Raj Bhan, managing this fund for 21.4 years.
Where this fund sits
Its shelf, all funds
St · Sectoral / thematic →
One sector, one story. The most-launched shelf on the map, by far.
The money map
How big this shelf is in India →
The whole industry sized by real money, from AMFI’s monthly data.
Side by side
Compare this fund →
Put it next to any other fund — growth, returns, risk and cost in one table.
One bet or two?
Check its overlap →
See whether it owns the same stocks as your other funds.
Other Sectoral/ Thematic funds
- ICICI Prudential India Opportunities Fund₹38,299 crore
- ICICI Prudential Business Cycle Fund₹16,123 crore
- Tata Digital India Fund₹10,214 crore
- Franklin India Opportunities Fund₹9,344 crore
- SBI Energy Opportunities Fund₹8,647 crore
- ICICI Prudential Infrastructure Fund₹8,523 crore
- Nippon India Power & Infra Fund₹8,042 crore
- Nippon India Banking & Financial Services Fund₹7,774 crore
Data: NYVO research systems; each block above states its own as-of date, and blocks with no data for this fund are omitted rather than estimated. NAV updates daily on working days. The benchmark (Nifty Pharma TRI) is named for reference only; its values are licensed and never shown. This page is factual information about one scheme. It is not investment advice, not a recommendation, and it carries no rating of any kind. Past performance does not predict future returns. Mutual fund investments are subject to market risks; read all scheme related documents carefully.